Patents by Inventor Jingtai Cao
Jingtai Cao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220132818Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: ApplicationFiled: October 20, 2021Publication date: May 5, 2022Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
-
Patent number: 11178860Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: GrantFiled: October 21, 2019Date of Patent: November 23, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
-
Publication number: 20210307304Abstract: Non-human animals suitable for use as animal models for Retinoschisis are provided. In some embodiments, provided non-human animals are characterized by a disruption in a Retinoschisin-1 locus. In some embodiments, provided non-human animals are characterized by a mutant Retinoschisin-1 gene. The non-human animals may be described, in some embodiments, as having a phenotype that includes the development of one or more symptoms or phenotypes associated with Retinoschisis. Methods of identifying therapeutic candidates that may be used to prevent, delay or treat Retinoschisis or eye-related diseases, disorders or conditions are also provided.Type: ApplicationFiled: June 16, 2021Publication date: October 7, 2021Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Susannah Brydges, Yajun Tang, Yang Liu, Jingtai Cao, Carmelo Romano
-
Patent number: 11104730Abstract: The present disclosure provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present disclosure comprise administering to a subject in need thereof a therapeutic composition comprising an APLNR antagonist such as an anti-APLNR antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (for example, aflibercept).Type: GrantFiled: May 4, 2018Date of Patent: August 31, 2021Assignee: Regeneren Pharmaceuticals, Inc.Inventors: Jingtai Cao, Eunice Cheung, Ivan B. Lobov
-
Patent number: 11071780Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).Type: GrantFiled: December 28, 2018Date of Patent: July 27, 2021Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Robert L. Vitti, Kristine A. Erickson, Karen W. Chu, Stanley J. Wiegand, Jingtai Cao, Ivan B. Lobov, Saurabh Wadhwa, Kenneth S. Graham, Daniel Dix
-
Patent number: 11064685Abstract: Non-human animals suitable for use as animal models for Retinoschisis are provided. In some embodiments, provided non-human animals are characterized by a disruption in a Retinoschisin-1 locus. In some embodiments, provided non-human animals are characterized by a mutant Retinoschisin-1 gene. The non-human animals may be described, in some embodiments, as having a phenotype that includes the development of one or more symptoms or phenotypes associated with Retinoschisis. Methods of identifying therapeutic candidates that may be used to prevent, delay or treat Retinoschisis or eye-related diseases, disorders or conditions are also provided.Type: GrantFiled: February 26, 2018Date of Patent: July 20, 2021Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Susannah Brydges, Yajun Tang, Yang Liu, Jingtai Cao, Carmelo Romano
-
Publication number: 20200037587Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: ApplicationFiled: October 21, 2019Publication date: February 6, 2020Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
-
Patent number: 10524458Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: GrantFiled: July 2, 2018Date of Patent: January 7, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
-
Patent number: 10492477Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: GrantFiled: July 26, 2017Date of Patent: December 3, 2019Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew Murphy
-
Publication number: 20190117767Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).Type: ApplicationFiled: December 28, 2018Publication date: April 25, 2019Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX
-
Publication number: 20180332833Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: ApplicationFiled: July 2, 2018Publication date: November 22, 2018Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
-
Publication number: 20180255754Abstract: Non-human animals suitable for use as animal models for Retinoschisis are provided. In some embodiments, provided non-human animals are characterized by a disruption in a Retinoschisin-1 locus. In some embodiments, provided non-human animals are characterized by a mutant Retinoschisin-1 gene. The non-human animals may be described, in some embodiments, as having a phenotype that includes the development of one or more symptoms or phenotypes associated with Retinoschisis. Methods of identifying therapeutic candidates that may be used to prevent, delay or treat Retinoschisis or eye-related diseases, disorders or conditions are also provided.Type: ApplicationFiled: February 26, 2018Publication date: September 13, 2018Inventors: Susannah Brydges, Yajun Tang, Yang Liu, Jingtai Cao, Carmelo Romano
-
Publication number: 20180251545Abstract: The present disclosure provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present disclosure comprise administering to a subject in need thereof a therapeutic composition comprising an APLNR antagonist such as an anti-APLNR antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (for example, aflibercept).Type: ApplicationFiled: May 4, 2018Publication date: September 6, 2018Inventors: Jingtai CAO, Eunice CHEUNG, Ivan B. LOBOV
-
Publication number: 20170360013Abstract: Provided herein are methods for creating an animal model for the study of dry eye and methods of using such animal models to test candidate treatments for ocular conditions and determine the efficacy of such treatments.Type: ApplicationFiled: December 1, 2015Publication date: December 21, 2017Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Ming YUAN, Ying HU, Jingtai CAO, Carmelo ROMANO
-
Publication number: 20170332611Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: ApplicationFiled: July 26, 2017Publication date: November 23, 2017Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew Murphy
-
Patent number: 9795121Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: GrantFiled: May 4, 2015Date of Patent: October 24, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, John McWhirter, Andrew Murphy, Lynn Macdonald
-
Publication number: 20170080086Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).Type: ApplicationFiled: December 6, 2016Publication date: March 23, 2017Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX
-
Publication number: 20160152717Abstract: The present invention provides methods for treating dry eye disease by administering an IL-6R antagonist to a subject in need thereof.Type: ApplicationFiled: December 1, 2015Publication date: June 2, 2016Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Jingtai CAO, Ying HU, Carmelo ROMANO, Stanley J. WIEGAND
-
Publication number: 20160144025Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).Type: ApplicationFiled: November 17, 2015Publication date: May 26, 2016Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX
-
Publication number: 20150313194Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: ApplicationFiled: May 4, 2015Publication date: November 5, 2015Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, John McWhirter, Andrew Murphy, Lynn Macdonald